Zafirlukast (Accolate) in asthma  
Booth-Clibborn N, Best L, Stevens A

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
Booth-Clibborn N, Best L, Stevens A. Zafirlukast (Accolate) in asthma. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1996

Authors' objectives
The author evaluates whether zafirlukast should be offered to patients with mild to moderate asthma, who are currently treated at Step 2 of the British Thoracic Society guidelines, ie. prescribed bronchodilators and corticosteroids.

Authors' conclusions
The authors conclude that corticosteroids are likely to remain the major treatment for mild to moderate asthma patients for the near future. There is insufficient evidence of zafirlukast's effectiveness in long-term management and for routine use as Step 2 treatment, but results of direct comparative trials with corticosteroids are awaited.

Project page URL
http://www.wihrd.soton.ac.uk

Indexing Status
Subject indexing assigned by CRD

MeSH
Adrenal Cortex Hormones; Anti-Asthmatic Agents /therapeutic use; Asthma /drug therapy; Costs and Cost Analysis; Receptors, Leukotriene /antagonists & inhibitors

Language Published
English

Country of organisation
England

Address for correspondence
Pauline King, Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton SO16 7PX. Tel. +44 1703 595661 Fax +44 1703 595662

AccessionNumber
31998008882

Date bibliographic record published
11/08/1998

Date abstract record published
11/08/1998